Latest Approvals News

Page 1 of 1286
North Carolina regulators have approved Duke Energy’s rate settlements, authorising billions of dollars of investment while reducing the revenue increases the utilities initially sought. New rules for large data centre customers add protection against early exits and network costs, but final revenue calculations remain outstanding.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Global Lithium’s proposed Titan Australia Mining takeover has cleared a procedural court hurdle, with shareholders now set to vote on the scheme in December. The transaction remains subject to shareholder approval and further conditions, with the Scheme Booklet and independent expert’s report still to be released.
Maxwell Dee
Maxwell Dee
17 Nov 2026
MA Credit Income Trust has opened a voluntary off-market buy-back for up to 1.25% of its units, giving eligible investors another way to exit at the trust’s net asset value. The final price will be set on 31 December, while acceptances may be scaled back or rejected at the responsible entity’s discretion.
Claire Turing
Claire Turing
17 Nov 2026
Vault Minerals’ merger with Genesis Minerals has cleared its final legal hurdle and is now legally effective, setting the transaction on course for implementation next week. Vault shares are expected to stop trading after 17 November, while the final consideration mix and any scaleback remain unresolved.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Jameson Resources has moved Crown Mountain into the final stage of British Columbia’s environmental assessment process, with an Environmental Certificate targeted for the first half of 2027. The proposed steelmaking coal mine still depends on regulatory approval, Indigenous partnership agreements, project funding and a final investment decision.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Aspermont has told ASX that directors John Stark and Graeme McCracken failed to obtain prior approval or notify the company of transactions, leading to late Appendix 3Y notices. ASX raised possible listing rule and Corporations Act breaches, although no penalty or formal finding has been disclosed.
Victor Sage
Victor Sage
17 Nov 2026
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
Finbar has completed the $7.5 million acquisition of a 5,317-square-metre Ascot site, where it is targeting more than 200 apartments and 500 square metres of commercial space. The proposed project carries an estimated end value of $166 million, but its final yield, design and approvals are still to be determined.
Victor Sage
Victor Sage
17 Nov 2026
Corazon Mining is evaluating a build-own-operate carbon-in-leach plant at its Chalice Gold Project, with an initial 600,000-tonne annual capacity and expansion potential to 1.8 million tonnes. The proposal could reduce upfront processing capital, but remains non-binding and depends on metallurgy, approvals, funding and a definitive contract.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Sandon Capital Investments is promoting a 7.8% fully franked dividend yield and a 7.2% discount to pre-tax NTA, while acknowledging that QPM Energy’s administration cost its portfolio about 7%. The listed investment company says its long-term record and activist holdings continue to offer value, but recent performance has lagged key benchmarks.
Claire Turing
Claire Turing
17 Nov 2026
Actinogen Medical’s shares have been suspended while it completes analysis of additional data from its pivotal XanaMIA Alzheimer’s trial. The company expects trading to resume no later than 19 November unless the results announcement comes first.
Ada Torres
Ada Torres
17 Nov 2026
Island Pharmaceuticals is moving Galidesivir into a decisive sequence of Marburg animal studies after the FDA confirmed an Animal Rule pathway for the antiviral. The company also expects to generate prospective human data through an approved Uganda Ebola program, although approval, funding and commercial outcomes remain unresolved.
Victor Sage
Victor Sage
17 Nov 2026

Browse the archive

Full archive